Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Storage of Bile From Routine Procedures to Study Risk Factors

This study has been terminated.
(Decreasing interest in using samples; department infrastructure waned)
Sponsor:
Information provided by (Responsible Party):
Indiana University ( Indiana University School of Medicine )
ClinicalTrials.gov Identifier:
NCT00414843
First received: December 21, 2006
Last updated: February 22, 2016
Last verified: February 2016
  Purpose
The purpose of the study is to establish a repository of human bile as a resource for studies evaluating molecular predictors of biliary cancer risk.

Condition
Gallbladder Cancer
Cholangiocarcinoma
Biliary Tract Cancer

Study Type: Observational
Official Title: A Prospective Study of Human Bile and Molecular Predictors of Biliary Malignancy Risk

Resource links provided by NLM:


Further study details as provided by Indiana University:

Primary Outcome Measures:
  • Establish Repository of Human Bile [ Time Frame: 2024 ] [ Designated as safety issue: No ]
    Establish a repository of human bile that will serve as a resource through which studies can be performed looking at molecular predictors of biliary tract cancer risk.


Biospecimen Retention:   Samples Without DNA
Bile, plasma

Enrollment: 390
Study Start Date: December 2006
Study Completion Date: August 2015
Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Detailed Description:
The specific aim of this study is to establish a repository of human bile to serve as a resource for studies looking at molecular predictors of biliary tract cancer. The development of fluid based biomarkers will enable early diagnosis in at-risk individuals with a recognized risk factor for cholangiocarcinoma, as well as provide surveillance mechanisms for screening populations where biliary tract cancer has a high incidence.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects presenting to Indiana University for treatment of biliary tract disease.
Criteria

Inclusion Criteria:

  • Presenting to IU for treatment of biliary tract disease; Age greater than or equal to 18

Exclusion Criteria:

  • Problems other than biliary tract disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00414843

Locations
United States, Indiana
Indiana University Hospital
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University School of Medicine
Investigators
Principal Investigator: Mary Maluccio, MD Indiana University
  More Information

Responsible Party: Indiana University School of Medicine
ClinicalTrials.gov Identifier: NCT00414843     History of Changes
Other Study ID Numbers: 0611-55  IUCRO-0176 
Study First Received: December 21, 2006
Last Updated: February 22, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Indiana University:
Storage
Bile
Biomarkers
biliary malignancies

Additional relevant MeSH terms:
Cholangiocarcinoma
Gallbladder Neoplasms
Biliary Tract Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Biliary Tract Diseases
Digestive System Diseases
Gallbladder Diseases

ClinicalTrials.gov processed this record on September 26, 2016